A glutamatergic network mediates lithium response in bipolar disorder as defined by epigenome pathway analysis

Pharmacogenomics

Volumn 16, Issue 14, 2015, Pages 1547-1563

  Higgins, Gerald A ^a,b   Allyn Feuer, Ari ^a   Barbour, Edward ^a   Athey, Brian D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Assurex Health Inc ^*  (United States)

Author keywords

bioinformatics; bipolar disorder; circadian rhythmicity; epigenome roadmap consortium; in silico analysis; lithium response; pharmacodynamics; pharmacoepigenomics

Indexed keywords

AMPA RECEPTOR; ANKYRIN; ANKYRIN 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EXCITATORY AMINO ACID TRANSPORTER 2; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM SALT; MESSENGER RNA; METABOTROPIC RECEPTOR; NUCLEAR RECEPTOR NR1D1; RNA; TRANSCRIPTION FACTOR ARNTL; UNCLASSIFIED DRUG; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 2; GLUTAMIC ACID; LITHIUM DERIVATIVE; TRANQUILIZER;

ANK3 GENE; ARNTL GENE; ARTICLE; BIPOLAR DISORDER; BRAIN REGION; CACNA1C GENE; CACNG2 GENE; CDKN1A GENE; CONTROLLED STUDY; CREB1 GENE; DRUG SAFETY; ENHANCER REGION; EPIGENETICS; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUTAMATERGIC NETWORK; GRIA2 GENE; GSK3B GENE; HUMAN; MENTAL DISEASE; NERVE CELL NETWORK; NR1D1 GENE; PHARMACOGENOMICS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC1A2 GENE; TISSUE SPECIFICITY; UNSPECIFIED SIDE EFFECT; UNTRANSLATED REGION; BIOSYNTHESIS; CHROMOSOMAL MAPPING; COMPUTER SIMULATION; GENETIC EPIGENESIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IN SITU HYBRIDIZATION; METABOLISM;

ANTIMANIC AGENTS; BIPOLAR DISORDER; CHROMOSOME MAPPING; COMPUTER SIMULATION; EPIGENESIS, GENETIC; GENOME-WIDE ASSOCIATION STUDY; GLUTAMIC ACID; HUMANS; IN SITU HYBRIDIZATION; LITHIUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, AMPA; RNA, MESSENGER;

EID: 84945578611     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.106     Document Type: Article

References (154)

1. Merikangas KR, Jin R, He JP et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry 68(3), 241-251 (2011).
2. Ladouceur CD Almeida JR, Birmaher B et al. Subcortical gray matter volume abnormalities in healthy bipolar offspring: potential neuroanatomical risk marker for bipolar disorder? J. Am. Acad. Child. Adolesc. Psychiatry 47, 532-539 (2008).
3. Grof P, Duffy A, Cavazzoni P et al. Is response to prophylactic lithium a familial trait? J. Clin. Psychiatry 63(10), 942-947 (2002).
4. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 13, 537-551 (2012).
5. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identifcation of risk loci with shared effects on fve major psychiatric disorders: a genome-wide analysis. Lancet 381(9875), 1371-1379 (2013).
6. Noga JT, Vladar K, Torrey EF. A volumetric magnetic resonance imaging study of monozygotic twins discordant for bipolar disorder. Psychiatry Res. 106(1), 25-34 (2004).
7. Petronis A, Gottesman II, Kan P et al. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr. Bull. 29(1), 169-178 (2003).
8. Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102(30), 10604-10609 (2005).
9. Bel JT, Spector TD. A twin approach to unraveling epigenetics. Trends Genet. 27(3), 116-125 (2011).
10. Rybakowski JK. Lithium: sixty years thereafter. Neuropsychobiology 62, 5-7 (2010).
11. Passmore MJ, Garnham J, Duffy A et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 5, 110-114 (2003).
12. Turecki G, Grof P, Grof E et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol. Psychiatry 6, 570-578 (2001).
13. Chen CH, Lee CS, Lee MT et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N. Engl. J. Med. 370(2), 119-128 (2014).
14. Tomita H, Yokooji Y, Ishibashi T, Imanaka T, Atomi H. An archaeal glutamate decarboxylase homolog functions as an aspartate decarboxylase and is involved in β-alanine and coenzyme A biosynthesis. J. Bacteriol. 196(6), 1222-1230 (2014).
15. Perlis RH, Smoller JW, Ferreira MA et al. A genome wide association study of response to lithium for prevention of recurrence in bipolar disorder. Am. J. Psychiatry 166, 718-725 (2009).
16. Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN. Deciphering the lithium transcriptome: microarray profling of lithium-modulated gene expression in human neuronal cells. Neuroscience 151, 1184-1197 (2008).
17. Du J, Creson TK, Wu LJ et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J. Neurosci. 28, 68-79 (2008).
18. Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci. Biobehav. Rev. 37(3), 418-435 (2013).
19. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
20. Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature 518, 317-330 (2015).
21. Leung D, Jung I, Rajagopal N et al. Integrative analysis of haplotype-resolved epigenomes across human tissues. Nature 518(7539), 350-354 (2015)
22. Rao SSP, Huntley MH, Durand NC et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 159, 1665-1680 (2014).
23. Jia P, Wang L, Meltzer HY, Zhaoa Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr. Res. 122, 38-42 (2010).
24. Shi G, Boerwinkle E, Morrison AC, Gu CC, Chakravarti A, Rao DC. Mining gold dust under the genome wide signifcance level: a two-stage approach to analysis of GWA S. Genet. Epidemiol. 35, 111-118 (2011).
25. Tasan M, Musso G, Hao T, Vidal M, MacRae CA, Roth FP. Selecting causal genes from genome-wide association studies via functionally coherent subnetworks. Nat. Methods 12(2), 154-159 (2015).
26. Califano A, Butte AJ, Friend S et al. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat. Genet. 44(8), 841-847 (2012).
27. McGeachie MJ, Clemmer GL, Lasky-Su J et al. Joint GWAS analysis: comparing similar GWAS at different genomic resolutions identifes novel pathway associations with six complex diseases. Genom. Data 2, 202-211 (2014).
28. Zhou K, Pearson ER. Insights from genome-wide association studies of drug response. Ann. Rev Pharmacol. Toxicol. 53, 299-310 (2013).
29. Kellis M, Wold B, Snyder MP et al. Defning functional DNA elements in the human genome. Proc. Natl Acad. Sci. USA 111(17), 6131-6138 (2014).
30. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu. Rev. Pharmacol. Toxicol. 53, 475-502 (2013).
31. Maurano MT, Humbert R, Rynes E et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337(6099), 1190-1195 (2012).
32. Roussos P, Mitchell AC, Voloudakis G et al. A role for noncoding variation in schizophrenia. Cell Rep. 9(4), 1417-1429 (2014).
33. Onengut-Gumuscu S, Chen WM, Burren O et al. Fine mapping of Type 1 diabetes susceptibility loci and evidence for co-localization of causal variants with lymphoid gene enhancers. Nat. Genet. 47(4), 381-386 (2015).
34. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat. Genet. 46 (11), 1160-1165 (2014).
35. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identifcation of risk loci with shared effects on fve major psychiatric disorders: a genome-wide analysis. Lancet 381(9875), 1371-1379 (2013).
36. Farh KK, Marson A, Zhu J et al. Genetic and epigenetic fne mapping of causal autoimmune disease variants. Nature 518, 337-343 (2015).
37. Crews D, Gillette R, Scarpino SV et al. Epigenetic transgenerational inheritance of altered stress responses. Proc. Natl Acad. Sci. USA 109(23), 9143-9148 (2012).
38. Dietz DM, LaPlant Q, Watts EL et al. Paternal transmission of stress-induced pathologies. Biol. Psychiatry 70, 408-414 (2011).
39. Peled E. Abused women who abuse their children: a critical review of the literature. Aggress. Violent Behavior 16(4), 325-330 (2011).
40. Kaufman J, Edward Z. Do abused children become abusive parents? Am. J. Orthopsychiatry 57(2), 186 (1987).
41. Larrance DT, Twentyman CT. Maternal attributions and child abuse. J. Abnormal Psychol. 92(4), 449 (1983).
42. Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 465, 721-727 (2010).
43. Slatkin M. Epigenetic inheritance and the missing heritability problem. Genetics 182(3), 845-850 (2009).
44. Labrie V, Pai S, Petronis A. Epigenetics of major psychosis: progress, problems and perspectives. Trends Genet. 28(9), 427-435 (2012).
45. Cortijo S, Wardenaar R, Colomé-Tatché M et al. Mapping the epigenetic basis of complex traits. Science 343 (6175), 1145-1148 (2014).
46. Badyaev AV. Epigenetic resolution of the 'curse of complexity' in adaptive evolution of complex traits. J. Physiol. 592(11), 2251-2260 (2014).
47. Parker SC, Stitzel ML, Taylor DL et al. Chromatin stretch enhancer states drive cell-specifc gene regulation and harbor human disease risk variants. Proc. Natl Acad. Sci. USA 110(44), 17921-17926 (2013).
48. Kumar V, Westra HJ, Karjalainen J et al. Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. PLoS Genet. 9 (1), e1003201 (2013).
49. Dekker J, Marti-Renom MA, Mirny LA. Exploring the three-dimensional organization of genomes: interpreting chromatin interaction data. Nat. Rev. Genet. 14, 390-403 (2013).
50. Jin F, Li Y, Dixon JR et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 503, 290-294 (2013).
51. Lieberman-Aiden E, van Berkum NL, Williams L et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289-293 (2009).
52. Deng W, Lee J, Wang H et al. Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor. Cell 149, 1233-1244 (2012).
53. Seitan VC, Faure AJ, Zhan Y et al. Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments. Genome Res. 223, 2066-2077 (2013).
54. Kleinjan DA, van Heyningen V. Long-range control of gene expression: emerging mechanisms and disruption in disease. Am. J. Hum. Genet. 76, 8-32 (2005).
55. Noordermeer D, de Wit E, Klous P et al. Variegated gene expression caused by cell-specifc long-range DNA interactions. Nat. Cell. Biol. 13(6), 944-954 (2011).
56. Li G, Ruan X, Auerbach RK et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 148(1-2), 84-98 (2012).
57. Cremer T, Cremer C. Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat. Rev. Genet. 2(4), 292-301 (2001).
58. Wendt KS, Grosveld FG. Transcription in the context of the 3D nucleus. Curr. Opin. Genet. Dev. 25, 62-67 (2014).
59. Aguilar-Arnal L, Sassone-Corsi P. Chromatin landscape and circadian dynamics: spatial and temporal organization of clock transcription. Proc. Natl Acad. Sci. USA 112(22), 6863-6870 (2015).
60. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotech. 28(8), 817-825 (2010).
61. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods 9, 215-216 (2012).
62. Hon G, Wang W, Ren B. Discovery and annotation of functional chromatin signatures in the human genome. PLoS Comput. Biol. 5, e1000566 (2009).
63. He HH, Meyer CA, Chen MW, Jordan VC, Brown M, Liu XS. Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res. 2, 1015-1025 (2012).
64. John S. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 43, 264-268 (2012).
65. Heyn H, Moran S, Hernando-Herraez I et al. DNA methylation contributes to natural human variation. Genome Res. 23(9), 1363-1372 (2013).
66. Hellman A, Chess A. Extensive sequence-Influenced DNA methylation polymorphism in the human genome. Epigenetics Chromatin 3, 11 (2010).
67. Kasowski M, Kyriazopoulou-Panagiotopoulou S, Grubert F et al. Extensive variation in chromatin states across humans. Science 342(6159), 750-752 (2013).
68. Shoemaker R, Deng J, Wang W, Zhang K. Allele-specifc methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res. 20, 883-889 (2010).
69. Schalkwyk LC, Meaburn EL, Smith R et al. Allelic skewing of DNA methylation is widespread across the genome. Am. J. Human Genet. 86, 196-212 (2010).
70. Kilpinen H, Waszak SM, Gschwind AR et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science 342 (6159), 744-747 (2013).
71. McVicker G, van de Geijn B, Degner JF et al. Identifcation of genetic variants that affect histone modifcations in human cells. Science 342, 747-749 (2013).
72. Jones MJ, Fejes AP, Kobor MS. DNA methylation, genotype and gene expression: who is driving and who is along for the ride? Genome Biol. 14(126), 1-3 (2013).
73. Flister MJ, Tsaih SW, O'Meara CC et al. Identifying multiple causative genes at a single GWAS locus. Genome Res. 23, 1996-2002 (2013).
74. Edwards SL, Beesley J, French JD, Dunning AM. Beyond GWAS: illuminating the dark road from association to function. Am. J. Human Genet. 93, 779-797 (2013).
75. Schaub MA, Boyle A P, Kundaje A, Batzoglou S, Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res. 22(9), 1748-1759 (2012).
76. Sunkin SM, Ng L, Lau C et al. Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res. 41, D996-D1008 (2013).
77. Zhou X, Li D, Zhang B et al. Epigenomic annotation of genetic variants using the Roadmap Epigenome Browser. Nat. Biotech. 33(4), 345-346 (2015).
78. Pomerantz J. Google Scholar and 100 percent availability of information. Info. Tech. Lib. 25(2), 52-56 (2013).
79. Lu Z. PubMed and beyond: a survey of web tools for searching biomedical literature. Database (Oxford) 2011, baq036 (2011).
80. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 41(D1), D377-D386 (2013).
81. Boyle AP, Hong EL, Hariharan M et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22(9), 1790-1797 (2012).
82. Wang Z, Jacobs KB, Yeager M et al. Improved imputation of common and uncommon SNPs with a new reference set. Nat. Genet. 44, 6-7 (2012).
83. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40(D1), D930-D934 (2012).
84. Higgins GA, Allyn-Feuer A, Athey BD. Epigenomic mapping and effect sizes of noncoding variants associated with psychotropic drug response. Pharmacogenomics doi:10.2217/pgs.15.105 (2015) (Epub ahead of print).
85. Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30(4), 523-530 (2014).
86. Cerami EG, Gross BE, Demir E et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 39(Suppl. 1), D685-D690 (2011).
87. Squassina A, Manchia M, Borg J et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 12, 1559-1569 (2011).
88. Cruceanu C, Ambalavanan A, Spiegelman D et al. Family-based exome-sequencing approach identifes rare susceptibility variants for lithium-responsive bipolar disorder. Genome 56, 634-640 (2013).
89. Dallaspezia S, Poletti S, Lorenzi C, Pirovano A, Colombo C, Benedetti F. Influence of an interaction between lithium salts and a functional polymorphism in SLC1A2 on the history of illness in bipolar disorder. Mol. Diagn. Therapy 16 (5), 303-309 (2012).
90. Rybakowski JK. Genetic Influences on response to mood stabilizers in bipolar disorder. CNS Drugs 27(3), 165-173 (2013).
91. Schulze T. The Consortium on Lithium Genetics (ConLiGen) genome-wide association studies of lithium response phenotypes in bipolar disorder [abstract book]. CINP Congress Stockholm 36, 3-7 (2012).
92. Rybakowski JK. Response to lithium in bipolar disorder: clinical and genetic fndings. ACS Chem. Neurosci. 5(6), 413-421 (2014).
93. Benedetti F, Serretti A, Pontiggia A et al. Long-term response to lithium salts in bipolar illness is Influenced by the glycogen synthase kinase 3-β-50 T/C SNP. Neurosci. Lett. 376(1) 51-55 (2005).
94. Lin YF, Huang MC, Liu HC. Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J. Affective Dis. 147(1-3), 401-406 (2013).
95. McCarthy MJ, Nievergelt CM, Shekhtman T, Kripke DF, Welsh DK, Kelsoe JR. Functional genetic variation in the REV-ERBA pathway and lithium response in the treatment of bipolar disorder. Genes Brain Behav. 10(8) 852-861 (2011).
96. McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics 11, 1439-1465 (2010).
97. Rybakowski JK, Dmitrzak-Weglarz M, Dembinska-Krajewska D, Hauser J, Akiskal KK, Akiskal HH. Polymorphism of circadian clock genes and temperamental dimensions of the TEMPS-A in bipolar disorder. J. Affect. Disord. 159, 80-84 (2014).
98. Byrne EM, Gehrman PR, Medland SE. A genome-wide association study of sleep habits and insomnia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B(5), 439-451 (2013).
99. Soronen P, Ollila HM, Antila M et al. Replication of GWAS of bipolar disorder: association of SNPs near CDH7 with bipolar disorder and visual processing. Mol. Psychiatry 15, 4-6 (2010).
100. Ferreira MA, O'Donovan MC, Meng YA et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40(9), 1056-1058 (2008).
101. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifes a new susceptibility locus near ODZ4. Nat. Genet. 43(10), 977-983 (2011).
102. Chen DT, Jiang X, Akula N et al. Genome-wide association study meta-analysis of European and Asian-ancestry samples identifes three novel loci associated with bipolar disorder. Mol. Psychiatry 18(2), 195-205 (2013).
103. Liu Y, Blackwood DH, Caesar S et al. Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. Mol. Psychiatry 16(1), 2-4 (2011).
104. Rietschel M, Mattheisen M, Frank J et al. Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol. Psychiatry 68(6) 578-585 (2010).
105. Green EK, Grozeva D, Forty L et al. Association at SYNE1 in both bipolar disorder and recurrent major depression. Mol. Psychiatry 18 (5), 614-617 (2013).
106. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifes fve new schizophrenia loci. Nat. Genet. 43 (10), 969-976 (2011).
107. Rueckert EH, Barker D, Ruderfer D et al. Cis-acting regulation of brain-specifc ANK3 gene expression by a genetic variant associated with bipolar disorder. Mol. Psychiatry 18 (8), 922-999 (2013).
108. Schumacher-Schuh AF, Altmann V, Rieck M et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 14 (3), 289-294 (2014).
109. Spellmann I, Rujescu D, Musil R et al. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J. Psychiatr. Res. 45(2), 234-241 (2011).
110. Schulze TG, Detera-Wadleigh SD, Akula N et al. Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Mol. Psychiatry 14(5), 487-491 (2009).
111. Thier S, Lorenz D, Nothnagel M et al. Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology 79(3), 243-248 (2012).
112. Crawford RR, Higdon AN, Casey DB, Good DE, Mungrue IN. Multiple lithium-dependent Brugada syndrome unmasking events in a bipolar patient. Clin. Case Rep. 3(1), 14-18 (2015).
113. Wright D, Salehian O. Brugada-type electrocardiographic changes induced by long-term lithiumuse. Circulation 122, e418-e419 (2010).
114. Darbar D, Yang T, Churchwell K, Wilde AA, Roden DM. Unmasking of Brugada syndrome by lithium. Circulation 112, 1527-1531 (2005).
115. Parsons MJ, Lester KJ, Barclay NL, Nolan PM, Eley TC, Gregory AM. Replication of genome-wide association studies (GWAS) loci for sleep in the British G1219 cohort. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 162B(5), 431-438 (2013).
116. Manchia M, Adli M, Akula N et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) report. PLoS ONE 8(6), e65636 (2013).
117. Phillips ML, Schwartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am. J. Psychiatry 171(8), 829-843 (2014).
118. Strakowski SM, Adler CM, Almeida J et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 14, 313-325 (2012).
119. Dima D, Jogia J, Collier D, Vassos E, Burdick KE, Frangou S. Independent modulation of engagement and connectivity of the facial network during affect processing by CACNA1C and ANK3 risk genes for bipolar disorder. JAMA Psychiatry 70(12), 1303-1311. (2013).
120. Ernst E, Kellis M. Large-scale imputation of epigenomic datasets for systematic annotation of diverse human tissues. Nat. Biotechnol. 33(4), 364-376 (2015).
121. Zhou X, Maricque B, Xie M et al. The human epigenome browser at Washington University. Nat. Methods 8(12), 989-990 (2011).
122. Frank RA, McRae AF, Pocklington AJ et al. Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. PLoS ONE 6 (4), e19011 (2011).
123. Cheng MC, Lu CL, Luu SU et al. Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia. PLoS ONE 5(12), e15107 (2010).
124. Zhao C, Eisinger BE, Driessen TM, Gammie SC. Addiction and reward-related genes show altered expression in the postpartum nucleus accumbens. Front. Behav. Neurosci. 8, 388 (2014).
125. Makino C, Fujii Y, Kikuta R et al. Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region. Am. J. Med. Genet. B Neuropsychiatr. Genet. 116(1), 17-22 (2003).
126. Chiesa A, Crisafulli C, Porcelli S et al. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur. Arch. Psychiatry Clin. Neurosci. 262, 305-311 (2012).
127. Selvakumar B, Huganir RL, Snyder SH. S-nitrosylation of stargazin regulates surface expression of AMPA-glutamate neurotransmitter receptors. Proc. Natl Acad. Sci. USA 106, 16440-16445 (2009).
128. Hafner AS, Penn AC, Grillo-Bosch D et al. Lengthening of the stargazin cytoplasmic tail increases synaptic transmission by promoting interaction to deeper domains of PSD-95. Neuron 86, 2, 475-489 (2015).
129. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S. AmiGO: online access to ontology and annotation data. Bioinformatics 25(2), 288-289 (2009).
130. Claussnitzer M, Dankel SN, Klocke B et al. Leveraging cross-species transcription factor binding site patterns: from diabetes risk loci to disease mechanisms. Cell 156(1), 343-358 (2014).
131. Smith KR, Kopeikina KJ, Fawcett-Patel JM et al. Psychiatric risk factor ANK3/Ankyrin-G nanodomains regulate the structure and function of glutamatergic synapses. Neuron 84(2), 399-415 (2015).
132. Krug A, Witt SH, Backes H. A genome-wide supported variant in C ACNA1C Influences hippocampal activation during episodic memory encoding and retrieval. Eur. Arch. Psychiatry Clin. Neurosci. 264(2), 103-110 (2014).
133. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6(12), 1664-1668 (1996).
134. Adli M, Hollinde DL, Stamm T et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta-50T/C single nucleotide polymorphism. Biol. Psychiatry 62(11), 1295-1302 (2007).
135. Benedetti F, Serretti A, Pontiggia A et al. Long-term response to lithium salts in bipolar illness is Influenced by the glycogen synthase kinase 3-beta-50 T//C SNP. Neurosci. Lett. 376, 51-55 (2005).
136. Lin YF, Huang MC, Liu HC. Glycogen synthase kinase 3beta gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J. Affect. Disord. 147(1) 401-406 (2013).
137. Benedetti F, Bollettini I, Barberi I et al. Lithium and GSK3-beta promoter gene variants Influence white matter microstructure in bipolar disorder. Neuropsychopharmacology 38(2), 313-327 (2013).
138. Valvezan AJ, Klein PS. GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front. Mol. Neurosci. 5, 1 (2012).
139. Brown KM, Tracy DK. Lithium: the pharmacodynamic actions of the amazing ion. Ther. Adv. Psychopharmacol. 3(3), 163-176 (2013).
140. Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol. Ther. 128(2), 281-304 (2010).
141. Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol. Biochem. Behav. 123, 3-16 (2014).
142. Sahar S, Zocchi L, Kinoshita C, Borrelli E, Sassone-Corsi P. Regulation of BMAL1 protein stability and circadian function by GSK3b-mediated phosphorylation. PLoS ONE 5(1), e8561 (2010).
143. Crisafulli C, Chiesa A, De Ronchi D et al. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. Neurosci. Lett. 6, 170-174 (2012).
144. Welter D, MacArthur J, Morales J et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucliec Acids Res. 42, D1001-D1006 (2014).
145. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29(2) 211-223 (1995).
146. Kuttikat A, Shenker N. Pharmacological modulation of central nociception in the management of chronic musculoskeletal pain. Pain Manag. 1(6), 549-556 (2011).
147. Chiesa A, Crisafulli C, Porcelli S. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur. Arch. Psychiatry Clin. Neurosci. 262, 305-311 (2012).
148. Zimmermann P, Brückl T, Nocon A et al. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am. J. Psychiatry 168 (10), 1107-1116 (2011).
149. Yehuda R, Cai G, Golier JA et al. Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. Biol. Psychiatry 66(7), 708-711 (2009).
150. Binder EB, Salyakina D, Lichtner P et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36(12), 1319-1325 (2004).
151. Lekman M, Laje G, Charney D et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR∗ D) Cohort. Biol. Psychiatry 63 (12), 1103-1110 (2008).
152. Malhi GS, Tanious M, Das P, Coulston CM, Berk M Potential mechanisms of action of lithium in bipolar disorder. CNS Drugs 27(2), 135-153 (2013).
153. Mrazek D. Psychiatric Pharmacogenomics. Oxford University Press (2010).
154. Hall-Flavin DK, Winner JG, Allen JD et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet. Genomics 23(10), 535-548 (2013).